Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA

Background Non-vitamin K oral anticoagulants (NOACs) have emerged as an attractive alternative to vitamin K antagonists for various thromboembolic indications. However, prescribed NOAC doses are often inconsistent with drug labeling and prescribers might not consider the potential risks associated w...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Sheikh-Taha, Marwan (author)
مؤلفون آخرون: Deeb, Mary E. (author)
التنسيق: article
منشور في: 2019
الوصول للمادة أونلاين:http://hdl.handle.net/10725/11361
https://doi.org/10.1007/s40256-018-0310-3
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://link.springer.com/article/10.1007/s40256-018-0310-3
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513488680910848
author Sheikh-Taha, Marwan
author2 Deeb, Mary E.
author2_role author
author_facet Sheikh-Taha, Marwan
Deeb, Mary E.
author_role author
dc.creator.none.fl_str_mv Sheikh-Taha, Marwan
Deeb, Mary E.
dc.date.none.fl_str_mv 2019-10-02T08:27:41Z
2019-10-02T08:27:41Z
2019
2019-10-02
dc.identifier.none.fl_str_mv 1179-187X
http://hdl.handle.net/10725/11361
https://doi.org/10.1007/s40256-018-0310-3
Sheikh-Taha, M., & Deeb, M. E. (2019). Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients. American Journal of Cardiovascular Drugs, 19(2), 195-201.
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://link.springer.com/article/10.1007/s40256-018-0310-3
dc.language.none.fl_str_mv en
dc.relation.none.fl_str_mv American Journal of Cardiovascular Drugs
dc.rights.*.fl_str_mv info:eu-repo/semantics/openAccess
dc.title.none.fl_str_mv Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA
a chart review of 909 patients
dc.type.none.fl_str_mv Article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
description Background Non-vitamin K oral anticoagulants (NOACs) have emerged as an attractive alternative to vitamin K antagonists for various thromboembolic indications. However, prescribed NOAC doses are often inconsistent with drug labeling and prescribers might not consider the potential risks associated with concomitant use of other drugs, which can compromise NOACs’ safety and effectiveness. Methods A retrospective chart review was conducted in a tertiary care center in USA over a 4-month period. We studied patients whose home medications included NOACs and assessed the appropriateness as per drug labeling, taking into consideration relevant clinical factors and concomitant drug intake. Results A total of 909 patients with a mean age of 70.6 ± 13.1 years, out of which 51.6% were males, were included. The majority of patients received NOACs for stroke prevention in atrial fibrillation (AF) (70.5%), or deep venous thrombosis/pulmonary embolism (DVT/PE) treatment (13.5%). The most common drug prescribed was apixaban (57.8%) followed by rivaroxaban (34.0%), and less frequently dabigatran (7.7%). Inappropriate dosing was significantly more frequent among older patients, those taking NOACs for AF, those taking a higher number of home medications, and those with a lower creatinine clearance. Seven hundred and six patients (77.67%) had at least one drug-NOAC interaction, out of which 515 were rated major interactions. Antiplatelets, amiodarone, non-steroidal anti-inflammatory medications, and calcium channel blockers were the most commonly interacting drugs. Conclusion A significant number of patients received NOACs at doses inconsistent with the package labeling or had clinically significant drug–drug interactions with NOACs. Efforts are warranted to improve appropriate dosing and avoid significant drug interactions.
eu_rights_str_mv openAccess
format article
id LAURepo_aec90edb7ecb17049e1faa1222ee7e9f
identifier_str_mv 1179-187X
Sheikh-Taha, M., & Deeb, M. E. (2019). Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients. American Journal of Cardiovascular Drugs, 19(2), 195-201.
language_invalid_str_mv en
network_acronym_str LAURepo
network_name_str Lebanese American University repository
oai_identifier_str oai:laur.lau.edu.lb:10725/11361
publishDate 2019
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
spelling Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USAa chart review of 909 patientsSheikh-Taha, MarwanDeeb, Mary E.Background Non-vitamin K oral anticoagulants (NOACs) have emerged as an attractive alternative to vitamin K antagonists for various thromboembolic indications. However, prescribed NOAC doses are often inconsistent with drug labeling and prescribers might not consider the potential risks associated with concomitant use of other drugs, which can compromise NOACs’ safety and effectiveness. Methods A retrospective chart review was conducted in a tertiary care center in USA over a 4-month period. We studied patients whose home medications included NOACs and assessed the appropriateness as per drug labeling, taking into consideration relevant clinical factors and concomitant drug intake. Results A total of 909 patients with a mean age of 70.6 ± 13.1 years, out of which 51.6% were males, were included. The majority of patients received NOACs for stroke prevention in atrial fibrillation (AF) (70.5%), or deep venous thrombosis/pulmonary embolism (DVT/PE) treatment (13.5%). The most common drug prescribed was apixaban (57.8%) followed by rivaroxaban (34.0%), and less frequently dabigatran (7.7%). Inappropriate dosing was significantly more frequent among older patients, those taking NOACs for AF, those taking a higher number of home medications, and those with a lower creatinine clearance. Seven hundred and six patients (77.67%) had at least one drug-NOAC interaction, out of which 515 were rated major interactions. Antiplatelets, amiodarone, non-steroidal anti-inflammatory medications, and calcium channel blockers were the most commonly interacting drugs. Conclusion A significant number of patients received NOACs at doses inconsistent with the package labeling or had clinically significant drug–drug interactions with NOACs. Efforts are warranted to improve appropriate dosing and avoid significant drug interactions.PublishedN/A2019-10-02T08:27:41Z2019-10-02T08:27:41Z20192019-10-02Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1179-187Xhttp://hdl.handle.net/10725/11361https://doi.org/10.1007/s40256-018-0310-3Sheikh-Taha, M., & Deeb, M. E. (2019). Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients. American Journal of Cardiovascular Drugs, 19(2), 195-201.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://link.springer.com/article/10.1007/s40256-018-0310-3enAmerican Journal of Cardiovascular Drugsinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/113612021-03-19T10:47:37Z
spellingShingle Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA
Sheikh-Taha, Marwan
status_str publishedVersion
title Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA
title_full Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA
title_fullStr Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA
title_full_unstemmed Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA
title_short Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA
title_sort Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA
url http://hdl.handle.net/10725/11361
https://doi.org/10.1007/s40256-018-0310-3
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://link.springer.com/article/10.1007/s40256-018-0310-3